Cyprotex plc Company Profile (LON:CRX)

Analyst Ratings

Consensus Ratings for Cyprotex plc (LON:CRX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cyprotex plc (LON:CRX)
Show:
DateFirmActionRatingPrice TargetActions
11/17/2015N+1 SingerReiterated RatingcorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Cyprotex plc (LON:CRX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Cyprotex plc (LON:CRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cyprotex plc (LON:CRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cyprotex plc (LON:CRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cyprotex plc (LON:CRX)
DateHeadline
07/07/16 03:27 PMCyprotex : Launch New Endocrine Disruption Service
07/07/16 05:01 AMCyprotex Launch New Endocrine Disruption Service - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of a new endocrine disruption service to evaluate androgen ...
06/23/16 09:10 AMLaunch of New Endocrine Disruption Service
06/23/16 05:39 AMLaunch of chemTarget for Predicting Biological Target Interaction directly from Chemical Structure - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') 16 June 2016; Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of chemTarget, a virtual screening tool for ...
06/16/16 08:43 PMLaunch of chemTarget
06/16/16 07:48 AMCyprotex : Purchase New IntelliCyt iQue® Screener for Expansion of Cell-Based Services
06/16/16 04:49 AMCyprotex Purchase New IntelliCyt iQue® Screener for Expansion of Cell-Based Services - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') Cyprotex Purchase New IntelliCyt iQue Screener for Expansion of Cell-Based Services Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), ...
05/20/16 04:23 AMLaunch of New Enhanced Version of chemPK™ Workflow Solution for Predicting Human Pharmacokinetics Directly from Chemical Structure - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') Launch of New Enhanced Version of chemPK™ Workflow Solution for Predicting Human Pharmacokinetics Directly from Chemical Structure Cyprotex PLC (AIM:CRX), a specialist ...
05/17/16 12:59 PMCyprotex : Launch of GLP-Compliant Genotoxicity Services - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of GLP-compliant genotoxicity services. The new services will be offered from its Kalamazoo laboratories in Michigan in the USA.
05/17/16 04:02 AMLaunch of GLP-Compliant Genotoxicity Services - [at noodls] - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of GLP-compliant genotoxicity services. The new services will be offered from its ...
05/10/16 12:37 PMRisers & Fallers: Patagonia Gold, ITM Power, Cardiff Property, Sound Energy, Venn Life Sciences, CloudTag - The car seller's half-year results showed revenue and profits substantially up on the same period a year earlier. Cyprotex PLC (LON:CRX), up 10%. The pre-clinical toxicology specialist's performance in the first quarter was significantly ahead of the board ...
04/05/16 01:17 PMCyprotex Plc :CRX-GB: Earnings Analysis: For the six months ended December 31, 2015 -
04/05/16 12:49 PMCyprotex Plc :CRX-GB: Earnings Analysis: 2015 By the Numbers -
04/04/16 06:36 AMForm 8.3 - Cyprotex Plc -
03/31/16 11:36 AMLaunch of Advanced 3D Liver Model - Cyprotex PLC (AIM:CRX; www.cyprotex.com), a specialist ADME-Tox and Bioscience Contract Research Organisation (CRO), today announces the launch of an advanced 3D liver model for detecting hepatotoxic potential. Hepatotoxicity is a major cause of drug ...
03/31/16 11:36 AMCyprotex : Launch of New Chemical and Cosmetics Testing Guide - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of their new 'Chemical and Cosmetics Testing' guide. The guide is focused in the field of chemical (including pesticides and industrial ...
03/31/16 11:27 AMCyprotex unveils new 3D liver model -
03/09/16 10:44 AMLaunch of New Chemical and Cosmetics Testing Guide - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of their new 'Chemical and Cosmetics Testing' guide. The guide is focused in the field of chemical (including pesticides and ...
12/07/15 02:07 PMCyprotex Plc – Value Analysis (LONDON:CRX) : December 7, 2015 -
11/27/15 08:15 AMLaunch of New Solution to Predict Preclinical Toxicity - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of its new in silico modelling solution, chemTox, which ...
10/23/15 06:11 AMCyprotex expects full year results to be ahead of expectations -
10/15/15 08:02 AMCyprotex PLC - Partnership in the EC funded EU-ToxRisk consortium - [at noodls] - Cyprotex PLC ('Cyprotex' or 'the Company') Partnership in the EC funded EU-ToxRisk consortium Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces ...
07/16/15 10:43 AMCyprotex launches new chemPKTM workflow solution to predict human pharmacokinetics directly from chemical structure - [at noodls] - Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of its new predictive modelling solution, which predicts human pharmacokinetics directly from chemical ...
07/16/15 04:06 AMCyprotex launches new Biosciences division -
04/15/15 11:51 AMCyprotex posts operating loss for first time in 7 years after contract delays in the US -
04/01/15 07:44 AMCyprotex launches new high throughput laboratory in its US facility - [at noodls] - 31st March, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a new high throughput screening laboratory at its US facility in Watertown ...
03/19/15 04:25 AMCyprotex launch Short Time Exposure service for identifying potential serious eye damage for new chemicals - [at noodls] - Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announce the launch of a new in vitro testing service, the Short Time Exposure (STE) assay for identifying potential ...
03/12/15 04:39 AMCyprotex appoints Dr Rob Elsby as Leader of Drug Transporter Team - [at noodls] - Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the appointment of Dr Rob Elsby as Leader of its Drug Transporter Team. Dr Elsby is a recognised expert ...

Social

About Cyprotex plc

Cyprotex plc logoCyprotex PLC (Cyprotex) is a United Kingdom-based holding company. The Company is engaged in providing in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) information to various industries including the pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries and academia. The Company's trading subsidiaries are Cyprotex Discovery Limited and Cyprotex US, LLC (formerly Apredica LLC. Cyprotex provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: CRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.82
  • 50 Day Moving Average: $116.55
  • 200 Day Moving Average: $103.46
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $30.78M
  • Current Year EPS Consensus Estimate: $6.40 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: